1. Generics Bulletin
  2. >>Business

Goldman Ends Endo Coverage Following Q2 EBITDA Guide

NY-Based Investment Bank Halves Its 2023 Vasostrict Sales Guide

 
• By Dean Rudge

One of the largest investment banks in the US has cancelled its coverage of Endo after the US-based firm revealed the extent of generic competition to its lucrative Vasostrict brand.

Endo shares had been 'sent reeling' • Source: 360b/Shutterstock

Goldman Sachs is to cease coverage of struggling Endo International plc. The move follows the US-based firm guiding for its adjusted EBITDA to fall by as much as 65% quarter-over-quarter in the wake of generic competition to its $900m Vasostrict (vasopressin) injectable.

The New York-based investment bank typically publishes a report of Endo’s quarterly financial results and other material events

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Generics Bulletin

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.